EU regulators to probe Johnson & Johnson's Takeda deal

© Reuters. FILE PHOTO: The company logo for Johnson & Johnson is displayed on a screen to celebrate the 75th anniversary of the company’s listing at the NYSE in New York


BRUSSELS (Reuters) – EU antitrust regulators opened on Wednesday a full-scale investigation into Johnson & Johnson’s (N:) buy of Takeda Pharmaceutical Co’s (T:) surgical patch product TachoSil, saying the deal may hurt competition and innovation.

The European Commission set an Aug. 10 deadline for its decision on the deal.

Japan’s biggest drugmaker announced the disposal of $10 billion (8.6 billion pounds) worth of assets to cut debt in May last year, and also said it was selling TachoSil, a surgical patch for bleeding control, to Johnson & Johnson’s Ethicon for $400 million.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

READ  U.S. Consumer Credit Growth in March Was Slowest in Nine Months



Please enter your comment!
Please enter your name here